MyLumineyes · Global Rights & Attribution

Copyright & Content Use Policy

MyLumineyes® publishes original clinical, scientific and educational material for an international audience. Public accessibility does not place that material in the public domain. Copyright and other applicable rights are reserved internationally to the fullest extent provided by applicable national law, international treaties and regional intellectual-property law.

International rights reserved Limited quotation permitted Attribution required No unauthorized derivative use AI / TDM rights reserved where applicable

Core principle

You may cite the work. You may not appropriate it.

Limited quotation for scholarship, criticism, education, journalism or similar legitimate purposes may be made where permitted by applicable law, provided that the use is proportionate to its purpose and the original author and source are clearly identified.

Attribution does not create permission to reproduce, republish, translate, adapt, redesign, commercialize or redistribute a substantial part of MyLumineyes® content, nor does it authorize another person or organization to adopt an original MyLumineyes research framework, terminology system or classification as its own.

Content use

Permitted reference versus unauthorized reuse

Generally permitted where lawful

Limited quotation proportionate to a scholarly, critical, educational or journalistic purpose.
Academic discussion of MyLumineyes® research concepts with proper attribution and citation.
Direct linking to an original MyLumineyes webpage, DOI or research record.
Nominative reference to an original framework or term solely to identify and discuss the originating work.
Independent criticism, comparison or commentary that does not reproduce a substantial protected portion of the original work.

Not authorized without permission

Reproduction or republication of substantial text, complete sections, figures, diagrams, tables, photographs or research pages.
Translation, adaptation, abridgement, redesign or creation of derivative versions of protected material.
Removal, concealment or alteration of author attribution, copyright information or source identification.
Commercial redistribution, resale, sublicensing or incorporation into another commercial product or service.
Presenting an original MyLumineyes framework, classification, terminology system or authored structure as independently created by another person or organization.
Systematic extraction or scraping of protected content except where an applicable non-waivable legal exception expressly permits it.

Original scientific terminology

Attribution is permitted. Appropriation is not.

MyLumineyes® research includes authored terminology, abbreviations, classifications and framework names developed within the work of Mustafa Mete, MD. These terms may be named and discussed in scholarly or professional work when their origin is accurately attributed. Unauthorized adoption as another party's own framework identity, methodology label, commercial designation or independently originated terminology is not permitted to the extent enforceable under applicable law.

Selective Stromal Melanin Modulation (SSMM) MyLumineyes terminology for the selective stromal melanin-modulation concept.

Lumineyes™ Iris Pigmentation Scale (LIPS) Proposed clinical iris-phenotyping terminology and classification.

Lumineyes Optical Architectural Typology (L-OAT) Original optical and architectural iris-phenotyping framework.

Lumineyes Anterior-Segment Safety Staging (L-SAFE) Original proposed anterior-segment safety staging framework.

Temporal Response Architecture (TRA) Original hypothesis-generating temporal-response framework.

Controlled Treatment-Related Pigment Response Terminology introduced within the MyLumineyes research framework.

Response-Guided Staged Treatment Terminology describing the staged and response-guided treatment architecture.

Additional original terminology This list is illustrative and does not limit protection or attribution requirements for other original terminology published in the archive.

Scholarly-use rule: A researcher may write, for example, “Selective Stromal Melanin Modulation (SSMM), as proposed by Mete…” and cite the originating work.The term may not be stripped of its provenance and presented as the user's own terminology, renamed and redistributed as a derivative framework, or used in a way that falsely implies authorship, ownership, affiliation or endorsement.

This policy does not claim that every isolated word, short phrase or abbreviation is independently protected by copyright in every jurisdiction. Protection and remedies may instead arise, depending on the circumstances, from copyright in the underlying authored work, trademark rights, unfair-competition law, passing-off principles, contractual rights or other applicable intellectual-property law.

Attribution

Citation does not transfer ownership

When MyLumineyes® research, terminology or scientific material is discussed, the originating author or framework should be identified at first substantive use. Where possible, a direct link, DOI or conventional scholarly citation should accompany the reference.

Example: Mete M. Selective Stromal Melanin Modulation (SSMM). MyLumineyes Research. Cite and link to the relevant originating research record.

Proper attribution permits identification and lawful quotation; it does not itself authorize substantial reproduction, adaptation or commercial reuse.

International protection

Applicable global legal framework

MyLumineyes® does not rely upon a single country's copyright law. Intellectual-property protection is territorial and the law applicable to a specific act may depend upon the jurisdiction in which protection is claimed, the location and nature of the use, and other facts.

Rights are therefore reserved to the fullest extent available under applicable international treaties, regional law and national copyright, trademark, unfair-competition and related legislation. The references below identify important examples and are not an exhaustive statement of every potentially applicable law.

Jurisdiction / instrument	Selected provisions	Relevance
Berne Convention	Articles 5, 9 and 10	International copyright framework; automatic protection, reproduction rights and limited quotation subject to applicable conditions.
WIPO Copyright Treaty	Articles 8 and 10	Addresses digital communication and making-available rights while recognizing lawful national limitations and exceptions.
European Union	Directive 2001/29/EC, Articles 2–3	Provides exclusive rights concerning reproduction and communication or making available to the public within the EU framework.
European Union	Directive (EU) 2019/790, Article 4(3)	Permits rights holders, where applicable, to expressly reserve rights against certain text-and-data-mining uses, including through machine-readable means for online content.
United States	17 U.S.C. §§ 106–107	Section 106 provides core exclusive copyright rights, including reproduction and derivative-work rights; Section 107 preserves the fact-specific fair-use limitation.
United Kingdom	Copyright, Designs and Patents Act 1988, §§ 16 and 30	Section 16 identifies restricted acts including copying, distribution, communication and adaptation; Section 30 provides fair-dealing rules for criticism, review and quotation.
Türkiye	Law No. 5846, Articles 21, 22 and 35	Addresses adaptation and reproduction rights and the conditions applicable to statutory quotation.
Türkiye	Law No. 5846, Articles 68 and 71	Contains civil and, for conduct satisfying the statutory elements, criminal enforcement provisions concerning specified infringements.
Türkiye	Turkish Commercial Code, Articles 54–55	May be relevant to misleading commercial conduct or unfair competition, depending on the circumstances.
Trademark / designation law	Applicable national and regional law	Names, marks and commercial identifiers may receive additional protection where statutory or acquired trademark rights exist.

These references summarize selected legal principles only. They are not a choice-of-law or jurisdiction clause and do not exclude any other protection, defence, exception or remedy available under the law applicable to a particular case.

Machine-readable rights reservation

AI training, text and data mining and automated extraction

To the fullest extent that applicable law permits a rights holder to reserve such uses, MyLumineyes® expressly reserves rights in relation to automated reproduction, extraction and text-and-data mining of protected website content.

Without prior authorization, protected material is not offered for commercial model training, generative-AI training, dataset compilation, embedding-corpus creation, model-development corpora or systematic machine extraction, except to the extent that an applicable mandatory statutory exception permits the relevant activity.

For content to which European Union law applies, this notice is intended to constitute an express reservation of rights for purposes including Article 4(3) of Directive (EU) 2019/790.

Unauthorized use

Infringing or misleading use may be challenged

Where appropriate and legally available, unauthorized reproduction, adaptation, republication, false attribution, commercial appropriation, removal of authorship information or misleading use of original research material may lead to requests for immediate removal, correction, preservation of evidence, platform or hosting-provider notices, claims for injunctive relief, monetary remedies and other remedies available under the applicable jurisdiction.

Depending upon the jurisdiction and facts, enforcement may be pursued under copyright, trademark, unfair-competition, passing-off, contractual or related intellectual-property law.

Nothing on this page suggests that a remedy is automatic. Liability, defences, exceptions, jurisdiction and remedies remain dependent upon the applicable law and individual circumstances.

Separate publication licences

A specific publication may have its own licence

Certain journal articles, repository deposits, preprints or DOI records may be distributed under a licence specific to that version of the work. Where a valid work-specific licence applies, its terms govern the licensed copy to the extent of the rights granted by that licence.

This website-wide policy does not revoke rights already granted under a valid work-specific licence and does not expand restrictions beyond those permitted by applicable law.

No waiver

Online publication is not a waiver of rights

Search-engine indexing, social-media sharing, hyperlinking, DOI assignment, public accessibility or publication within the MyLumineyes Research Archive does not, by itself, constitute abandonment, transfer or waiver of copyright or other applicable intellectual-property rights.

Permissions

Need to reproduce, translate or adapt material?

Permission requests should identify the exact material, intended use, publication or platform, territory, proposed modifications and whether the proposed use is commercial or non-commercial.

Contact MyLumineyes →

Policy notice: This page states the rights holder's intended position regarding attribution, copying, derivative use, terminology, commercial reuse and automated extraction. It does not create intellectual-property rights that do not otherwise exist under applicable law, does not restrict statutory rights or exceptions that cannot legally be excluded, and is not legal advice to any website visitor.